Journal of Psychoactive Drugs
November 9, 2025
James M Zech, Jérémie Richard, Grant Jones
Psychedelic-assisted interventions are emerging as potential treatments for substance use disorders, including alcohol use disorder (AUD). While recent randomized controlled trials suggest efficacy for certain psychedelics and related compounds in treating AUD, the impact of naturalistic psychedelic use on problematic alcohol consumption remains underexplored. This study examines associations...
Journal of Drug Issues
October 31, 2025
Blake Beaton
The emergence of microdosing introduced a novel approach to consuming classic psychedelic substances, such as LSD (lysergic acid diethylamide) and psilocybin mushrooms, in ways previously unconventional. Whereas traditional illicit substance use often seeks euphoric experiences, microdosing deliberately avoids such effects in favor of perceived self-enhancing benefits. Increasingly common in...
Pharmaceutical Science
October 13, 2025
Berta Fumàs, David Pubill, Raúl López‐arnau et al.
Substance Use Disorder (SUD) is a chronic, relapsing mental health condition characterized by compulsive substance use despite harmful consequences. According to the World Health Organization, in 2021, approximately 39.5 million individuals worldwide suffered from drug use disorders, contributing to an estimated 600,000 deaths annually. Moreover, current pharmacological treatment, such as...
Brazilian Journal of Implantology and Health Sciences
October 10, 2025
Pedro M. P. Raposo, Lucas Almeida Gonçalves, Ana Laura de Araújo Caetano et al.
A depressão é um transtorno de grande impacto clínico e social, frequentemente resistente ao tratamento convencional, o que motiva a busca por estratégias terapêuticas complementares. Psicodélicos como a psilocibina e o MDMA têm se destacado por induzir respostas rápidas e duradouras em sintomas depressivos. Esta revisão integrativa analisou 14 estudos publicados entre 2015 e 2024, selecionados...
Clinical Chemistry
October 1, 2025
Stephanie Marco
Abstract Background Psychedelic and dissociative drugs, including psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), and ketamine, have garnered significant interest for their therapeutic potential in treating various mental health disorders. However, their psychoactive properties pose substantial risks when used in contexts requiring unimpaired cognitive...
Brain Disorders
September 23, 2025
Matthew Halma, R. Levy, Joseph Varón
2 citations
Clinicians and researchers are showing increased interest in psychedelic-assisted therapy for patients who don't show improvement from using conventional antidepressants. This updated review integrates recent developments, including data on lesser-studied compounds like DMT and 5-MeO-DMT, findings from large clinical trials, and evolving regulatory landscapes. In treatment-resistant depression,...
ACS Chemical Neuroscience
September 3, 2025
Arabo A. Avanes, Hunter T Warren, Abinaya Senthil et al.
2 citations
Tropane alkaloids and their derivatives represent a diverse class of small molecules with a broad range of therapeutic applications. Many tropanes regulate synaptic levels of neuromodulators by interacting with monoamine transporters such as dopamine (DAT) and serotonin (SERT) transporters. While DAT inhibition plays an important role in the addictive potential of tropanes such as cocaine,...
British Journal of Pharmacology
September 2, 2025
Lucas M Wittenkeller, Gary A. Gudelsky, Theresa Winhusen et al.
3 citations
Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive processes with lasting effects. We aimed to characterise how psychedelics are currently being investigated to treat substance use disorders (SUDs). Additionally, we aimed...
Journal of Eating Disorders
September 2, 2025
Elena Koning, Riccardo Miceli Mcmillan, Aaron Keshen et al.
3 citations
Psychedelic-assisted therapy (PAT) is an emerging intervention in psychiatry, for which there is preliminary evidence for effectiveness in eating disorders (EDs). The subjective psychedelic experience is considered an important driver of positive outcomes following PAT; however, conventional study design approaches often overlook many of the nuances inherent to the experience. Consequently,...
Health policy (Amsterdam, Netherlands)
July 8, 2025
Ramesh Joga, Sravani Yerram, Jayasri Devi Patnam et al.
5 citations
Research into psychedelics has gained renewed interest due to their potential to address psychiatric, neurological, and other peripheral conditions. These substances offer long-term therapeutic benefits, contrasting with the side effects and limitations of current psychiatric medicines. This study examines the legislations and regulatory frameworks for psychedelics in Australia, Canada, The...